Carcinoma, Renal Cell  >>  Torisel (temsirolimus)  >>  Phase N/A
Welcome,         Profile    Billing    Logout  

5 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Torisel (temsirolimus) / Pfizer
NCT01404104: Neo-adjuvant Temsirolimus in Patients With Advanced Renal Cell Carcinoma

Completed
N/A
11
Canada
Temsirolimus (pre surgery), Temsirolimus
St. Joseph's Healthcare Hamilton, McMaster University, Pfizer
Renal Cell Carcinoma
08/14
08/14
NCT01367457: INHIBITOR: Retrospective Study Of Patients With Renal Cell Carcinoma And Mantle Cell Lymphoma Treated With Temsirolimus

Completed
N/A
243
Europe
Temsirolimus (Non-Interventional Study)
Pfizer
Carcinoma, Renal Cell, Lymphoma, Mantle-Cell
04/15
04/15
NCT01781442: A Post Marketing Surveillance As Required By Philippine Food And Drug Administration

Withdrawn
N/A
0
RoW
Temsirolimus
Pfizer
Renal Cell Carcinoma
06/15
06/15
NCT01210482: Temsirolimus (Torisel) Drug Use Investigation (Regulatory Post Marketing Commitment Plan)

Completed
N/A
1022
Japan
Temsirolimus, Torisel
Pfizer
Renal Cell Carcinoma
03/18
03/18
NCT01420601: Temsirolimus (Torisel) Special Investigation (Regulatory Post Marketing Commitment Plan)

Completed
N/A
133
Japan
Temsirolimus, Torisel
Pfizer
Renal Cell Carcinoma
03/18
03/18

Download Options